09:00 · 15 May 2026 FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary The FDA’s rejection of Replimune’s melanoma drug RP1 has sparked outrage among doctors and patients, with experts citing a 33% survival benefit in cli...